Condition
Ebstein Anomaly
Total Trials
3
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Observation
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Phase 1 (1)
Trial Status
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT05225311RecruitingPrimary
Fetal Ebstein Anomaly and Tricuspid Valve Dysplasia Registry
NCT02914171Phase 1CompletedPrimary
Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly
NCT01907971CompletedPrimary
Assessment of Left and Right Ventricular Function in Patients With Ebstein Anomaly With Different Echocardiographic Methods
Showing all 3 trials
Research Network
Common Treatments
- Observation1
- Autologous Bone Marrowderived Mononuclear Cells1
- Insertable Cardiac Monitor1
Active Sponsors
- University Hospital, Zürich1
- The Hospital for Sick Children1
- Timothy J. Nelson1
- Angela Oxenius1
Top Investigators
Mayo Clinic
Related Conditions
- Tricuspid Valve Dysplasia1